Search
Inavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigational[L51748,L51738] In February 2025, it was approved by Health Canada for the same indication. [L52605] … Inavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers.
Praziquantel
go.drugbank.com/drugs/DB01058ApprovedInvestigationalVet approved[A263201] The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat a child) makes it an integral to WHO's plan to eliminate schistosomiasis by 2030 … Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum.
Mixtures: Eqvalan Duo Oral Paste for HorseFactor XIII (human)
go.drugbank.com/drugs/DB12909ApprovedInvestigationalWhen activated by thrombin at the site of injury, the FXIII pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit. … Factor XIII (Human), available as the commercially available product Corifact, is approved by the Food and Drug Administration for routine prophylactic treatment and peri-operative management of surgical
Enalapril
go.drugbank.com/drugs/DB00584ApprovedInvestigationalVet approvedIt was developed from a targeted research programmed using molecular modelling. … Commonly marketed under the trade name Vasotec, enalapril was first approved by the FDA in 1985 for the management of hypertension, heart failure, and asymptomatic left ventricular dysfunction.
Categories: Antihypertensive Agents Indicated for HypertensionChronic Granulocytic Leukemias
go.drugbank.com/conditions/DBCOND0143005Drugs: CyclophosphamideSynonyms: Chronic myelogenous leukemia, no International Classification of Diseases for Oncology subtypeChloroform
go.drugbank.com/drugs/DB11387ApprovedVet approvedWithdrawnChloroform is part of the FDA drug products withdrawn or removed from the market for reasons of safety or effectiveness.[L43942] … It is a colorless, sweet-smelling, dense liquid that is produced on a large scale as a precursor to PTFE and refrigerants, but the latter application is declining.
Categories: Compounds used in a research, industrial, or household settingTetrachlorodecaoxide
go.drugbank.com/drugs/DB05389ApprovedThe trial is being conducted in Germany at the University of Heidelberg and the National Centre for Tumor Diseases. … WF10 is a chlorite-based, immunomodulating drug is developed by Nuvo Research Inc. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers.
Categories: Compounds used in a research, industrial, or household settingCholine C 11
go.drugbank.com/drugs/DB09277ApprovedCholine C 11 is a marker for cellular proliferation as its main molecule is a precursor for the biosynthesis of phospholipids which are essential components of all cell membranes. … [A32041] It was developed by MCPRF and FDA first approved in September 2012.
Elafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigational[L50768] On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC). … [L50773] The drug was also approved by the EMA on September 23, 2024.[L51878]
Relacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigational[L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089] … [A275455,L56096] By competitively blocking the glucocorticoid receptor, relacorilant prevents cortisol from activating anti-apoptotic survival pathways, thereby restoring the efficacy of cytotoxic therapies